One of the studies at IAS 2025 with difficult but very clear results reported by Adeodata Kekitiinwa from the Baylor Foundation Uganda, that taking TLD (tenofovir/lamivudine/dolutegravir) on a 5-on 2-off dosing in the BREATHER Plus study was not as effective as daily dosing.
These results were not expected as the original BREATHER study (PENTA-16), also in adolescents, showed that reduced dosing was both as effective as daily ART and was also preferred by participants.
Read the full news story at HIV i-Base.
All HIV i-Base reports from IAS 2025 can be accessed here.
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.